DURECT Corporation
http://www.durect.com
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From DURECT Corporation
Keeping Track: Targeted Oncologics Tepmetko, Ukoniq Cleared; Posimir Earns Opioid-Sparing Language
The latest US FDA approval news from the Pink Sheet’s US FDA Performance Tracker
Deal Watch: Merck's Busy Stretch Includes Collaborations With Dewpoint, Zymeworks
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.
Coronavirus Update: Regeneron Races Into Phase III Trial Of Antibodies To Block Coronavirus Infection
Regeneron and NIAID kick off a Phase III prevention trial for antibody cocktail REGN-COV2.
Opioid-Sparing Hopes, Efficacy Worries Drive Inconclusive Advisory Cmte. On Durect's Posimir
US FDA's advisors produce tie vote on bupivacaine extended-release solution for post-surgical analgesia; proponents valued its potential to to cut opioid use, while opponents questioned its efficacy.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals